Literature DB >> 34077488

Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis.

Germanus S Bah1, Sebastian Schneckener2, Steffen R Hahnel3, Nicolas H Bayang1, Helena Fieseler3, Gabriele M Schmuck3, Ralph Krebber4, Anouk Sarr5, Carsten Terjung6, Henrietta F Ngangyung1, David D Ekale1, Youssouf M Mfopit1, Lucien Rufener5, John Graham-Brown7, Vincent N Tanya1,8, Martin Glenschek-Sieberth9, Daniel Kulke3, Benjamin L Makepeace7.   

Abstract

Onchocerciasis (river blindness), caused by the filarial worm Onchocerca volvulus, is a neglected tropical disease mostly affecting sub-Saharan Africa and is responsible for >1.3 million years lived with disability. Current control relies almost entirely on ivermectin, which suppresses symptoms caused by the first-stage larvae (microfilariae) but does not kill the long-lived adults. Here, we evaluated emodepside, a semi-synthetic cyclooctadepsipeptide registered for deworming applications in companion animals, for activity against adult filariae (i.e., as a macrofilaricide). We demonstrate the equivalence of emodepside activity on SLO-1 potassium channels in Onchocerca volvulus and Onchocerca ochengi, its sister species from cattle. Evaluation of emodepside in cattle as single or 7-day treatments at two doses (0.15 and 0.75 mg/kg) revealed rapid activity against microfilariae, prolonged suppression of female worm fecundity, and macrofilaricidal effects by 18 months post treatment. The drug was well tolerated, causing only transiently increased blood glucose. Female adult worms were mostly paralyzed; however, some retained metabolic activity even in the multiple high-dose group. These data support ongoing clinical development of emodepside to treat river blindness.

Entities:  

Year:  2021        PMID: 34077488     DOI: 10.1371/journal.ppat.1009601

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  6 in total

1.  Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.

Authors:  Lisa Luu; Germanus S Bah; Ndode Herman Okah-Nnane; Catherine S Hartley; Alexandra F Glover; Tessa R Walsh; Lu-Yun Lian; Bin Zhan; Maria Elena Bottazzi; David Abraham; Nikolai Petrovsky; Nicolas Bayang; Bernard Tangwa; Rene Billingwe Ayiseh; Glory Enjong Mbah; David D Ekale; Vincent N Tanya; Sara Lustigman; Benjamin L Makepeace; John Graham-Brown
Journal:  Vaccines (Basel)       Date:  2022-05-27

Review 2.  Onchocerciasis drug development: from preclinical models to humans.

Authors:  Adela Ngwewondo; Ivan Scandale; Sabine Specht
Journal:  Parasitol Res       Date:  2021-10-13       Impact factor: 2.289

Review 3.  Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis.

Authors:  Alexandra Ehrens; Achim Hoerauf; Marc P Hübner
Journal:  GMS Infect Dis       Date:  2022-03-30

Review 4.  Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi.

Authors:  Bin Zhan; Maria Elena Bottazzi; Peter J Hotez; Sara Lustigman
Journal:  Front Cell Infect Microbiol       Date:  2022-04-04       Impact factor: 6.073

Review 5.  Development of emodepside as a possible adulticidal treatment for human onchocerciasis-The fruit of a successful industrial-academic collaboration.

Authors:  Jürgen Krücken; Lindy Holden-Dye; Jennifer Keiser; Roger K Prichard; Simon Townson; Benjamin L Makepeace; Marc P Hübner; Steffen R Hahnel; Ivan Scandale; Achim Harder; Daniel Kulke
Journal:  PLoS Pathog       Date:  2021-07-22       Impact factor: 6.823

6.  Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside.

Authors:  Frauke Assmus; Richard M Hoglund; Frédéric Monnot; Sabine Specht; Ivan Scandale; Joel Tarning
Journal:  PLoS Negl Trop Dis       Date:  2022-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.